G-BA decisions from 22 November 2024
Here are the latest G-BA decisions from the G-BA meeting held on 22 Nov 2024 on the early benefit assessments of Voydeya,
Category: Uncategorized
G-BA decisions from 17 October 2024
Here are the latest G-BA decisions from the G-BA meeting held on 17 Oct 2024 on the early benefit assessments of Spexotras,
Insights on Germany’s Market Access – Interview with Market Access Today
In May 2024, I had the pleasure of being interviewed by Oznur Seyhun from Market Access Today.
G-BA implements another reimbursement restriction – Febuxostat in hyperuricemia
Most medicines are reimbursed at 100% from the day of launch in Germany, i.e. coverage by SHI funds is granted with the marketing authorization
G-BA criticises submitted data for assessments of pralsetinib and idecabtagen vicleucel
On 16 June 2022, the G-BA published its findings on the benefit assessments of Gavreto (pralsetinib) and Abecma (idecabtagen vicleucel). Both drugs